Cutaneous squamous cell carcinoma (cSCC) is the second most fatal skin tumor after melanoma. Positive results in advanced cSCC were reported at the end of 2017 for the immune checkpoint inhibitor cemiplimab, a human monoclonal antibody against the programmed cell death protein 1 (PD-1). However, convincing data for PD-1 blockers (pembrolizumab, nivolumab), which are primarily used for melanoma, are now available for the systemic treatment of cSCC as well. Basal cell carcinoma (BCC) is the most common form of skin cancer in Caucasians. Although it rarely metastasizes, it is more often locally inoperable. The approval of the hedgehog inhibitors vismodegib and sonidegib in 2012 and 2015, respectively, has made it possible to use effective oral targeted systemic therapy for metastatic or inoperable BCC. The first promising data on immune checkpoint blockers in BCC are also available.